Serial No.: 09/464,902

Filed December 16, 1999

Page 4

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-86. (Canceled)

- (Currently Amended) An isolated nucleic acid molecule 87. encoding one or more a polypeptide comprising consecutive amino acids the sequence of which is identical to the sequence of a CDR regions region of an anti-chemokine receptor 5 (CCR5) present in an anti-CCR5 antibody or a portion thereof, which antibody is selected from the group consisting of monoclonal antibody designated PA 14 (ATCC Accession No. HB-12610), monoclonal antibody designated PA 8 (ATCC Accession No. HB-12605), monoclonal antibody designated PA 9 (ATCC Accession No. HB-12606), monoclonal antibody designated PA 10 (ATCC Accession No. HB-12607), monoclonal antibody designated PA 11 (ATCC Accession No. HB-12608), or and monoclonal antibody designated PA 12 (ATCC Accession No. HB-12609).
- 88. (Previously Presented) The nucleic acid molecule of claim 87, wherein the nucleic acid molecule is an RNA molecule, DNA molecule or cDNA molecule.

89-90. (Canceled)

91. (Currently Amended) The nucleic acid molecule according to claim 87, wherein the CDR regions bind polypeptide

Serial No.: 09/464,902

Filed December 16, 1999

Page 5

<u>binds</u> to an epitope of CCR5, <u>said</u> <u>which</u> epitope comprises amino acid residues in (1) an N-terminus of CCR5, (2) <u>amino acid residues in</u> one of three extracellular loop regions of CCR5, or (3) a combination thereof.

- 92. (Currently Amended) The nucleic acid molecule according to claim 87, wherein the CDR region polypeptide is comprised within an Fab portion of the an antibody.
- 93. (Currently Amended) The nucleic acid molecule according to claim 87, wherein the CDR region polypeptide is comprised within a variable domain of the an antibody.
- 94. (Currently Amended) The nucleic acid molecule according to claim 87, wherein the CDR region polypeptide is comprised within an F(ab')₂ portion of the an antibody.
- 95. (Currently Amended) The nucleic acid molecule according to claim 87, wherein the nucleic acid coding the CDR region is comprised present in a hybridoma selected from the group of hybridomas consisting of PA 14 (ATCC Accession No. HB-12610), PA 8 (ATCC Accession No. HB-12605), PA 9 (ATCC Accession No. HB-12606), PA 10 (ATCC Accession No. HB-12607), PA 11 (ATCC Accession No. HB-12608), and PA 12 (ATCC Accession No. HB-12609).

96-97. (Canceled)

98. (Currently Amended) The nucleic acid molecule according to claim 96 95, wherein the portion of the antibody is an Fab portion of the antibody.

Serial No.: 09/464,902

Filed December 16, 1999

Page 6

99. (Currently Amended) The nucleic acid molecule according to claim 96 95, wherein the portion of the antibody is a variable domain of the antibody.

100. (Currently Amended) The nucleic acid molecule according to claim $\frac{96}{95}$, wherein the portion of the antibody is an $F(ab')_2$ portion of the antibody.

101. (Canceled)

- 102. (New) The nucleic acid molecule of claim 87, wherein the antibody is monoclonal antibody PA14.
- 103. (New) The nucleic acid molecule according to claim 87, wherein the polypeptide is a heavy chain of an antibody.
- 104. (New) The nucleic acid molecule according to claim 87, wherein the polypeptide is a light chain of an antibody.
- 105. (New) The nucleic acid molecule according to claim 87, wherein the polypeptide is a single chain antibody comprising heavy and light chains.
- 106. (New) The nucleic acid molecule according to claim 95, wherein the hybridoma is PA14 (ATCC Accession No. HB-12610).
- 107. (New) The nucleic acid molecule according to claim 95, wherein the portion of the antibody is a heavy chain.
- 108. (New) The nucleic acid molecule according to claim 95, wherein the portion of the antibody is a light chain.

Serial No.: 09/464,902

Filed December 16, 1999

Page 7

109. (New) The nucleic acid molecule according to claim 95, wherein the polypeptide is a single chain antibody comprising heavy and light chains.